Halozyme Therapeutics - HALO Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HALO shares.
View HALO analyst ratings or view top-rated stocks.

5 equities research analysts have issued 12-month target prices for Halozyme Therapeutics' stock. Their HALO share price forecasts range from $42.00 to $60.00. On average, they expect the company's share price to reach $52.67 in the next year. This suggests a possible upside of 26.4% from the stock's current price.
View analysts price targets for HALO or view top-rated stocks among Wall Street analysts.

Halozyme Therapeutics' stock was trading at $40.21 on January 1st, 2022. Since then, HALO shares have increased by 3.6% and is now trading at $41.66.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our HALO earnings forecast.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings data on Tuesday, August, 9th. The biopharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.06. The biopharmaceutical company had revenue of $152.37 million for the quarter, compared to analyst estimates of $156 million. Halozyme Therapeutics had a net margin of 75.11% and a trailing twelve-month return on equity of 101.73%. Halozyme Therapeutics's revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.63 EPS.

Halozyme Therapeutics updated its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided earnings per share (EPS) guidance of $2.10-$2.25 for the period, compared to the consensus estimate of $2.23. The company issued revenue guidance of $655.00 million-$685.00 million, compared to the consensus revenue estimate of $610.87 million.

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Halozyme Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include First Hawaiian Bank (0.02%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre.
View institutional ownership trends.

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HALO stock can currently be purchased for approximately $41.66.

Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $5.74 billion and generates $443.31 million in revenue each year. The biopharmaceutical company earns $402.71 million in net income (profit) each year or $2.53 on an earnings per share basis.

The company employs 145 workers across the globe.

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311.